Multiple myeloma (MM) is a B-cell malignancy characterized by the accumulation of a clone
of malignant plasma cells in the bone marrow. Despite recent advances in treatment …

Background: Multiple myeloma (MM) is characterized by genetic heterogeneity. The
cytogenetic abnormality t (4; 14) strongly predicts poor outcomes in MM patients. MM SET …

Multiple myeloma (MM), a hematologic malignancy, remains fatal despite all available
therapies. Initial treatment with conventional drugs effectively induces MM cell …

Ferroptosis is a non-apoptotic form of cell death caused by excessive iron exposure. The
role played by the ferroptosis-related genes and pathways in multiple myeloma (MM) is …

Multiple myeloma remains an incurable plasma cell neoplasm. New insights into its
pathogenesis have identified signaling pathways that have become potential therapeutic …

Background: Triple-class or penta-drug refractory Multiple Myeloma (MM) patients develop
multi-drug-resistant disease with poor survival. BCMA is a transmembrane receptor …

Multiple myeloma (MM) is a hematologic malignancy caused by the clonal expansion of
immunoglobulin-producing plasma cells in the bone marrow and/or extramedullary sites …

Multiple myeloma (MM) is a cancerous condition characterized by the proliferation of plasma
cells within the hematopoietic marrow, resulting in multiple osteolytic lesions. MM patients …

Multiple myeloma (MM) is a malignant plasma cell disorder, clinically characterized by
osteolytic lesions, immunodeficiency, and renal disease. Over the past decade, MM therapy …

In vitro and in vivo models have been developed that have allowed for delineation of
mechanisms of multiple myeloma (MM) cell homing to bone marrow (BM); tumor cell …